The Top Line
FDA Breakthrough Therapy and RMAT: Strategic Decisions That Can Accelerate Oncology Development (Sponsored)
June 16, 202620 min
Show notes
In this sponsored episode of The Top Line, host Stephanie Butler is joined by Sheila Plant, vice president of regulatory affairs at Allucent, to examine how FDA Breakthrough Therapy and RMAT designations can support more strategic oncology development. Although both pathways are intended to speed development, they are not interchangeable.
Transcript
Transcript not available for this episode yet.
More from The Top Line
Novo Nordisk’s CFO on the oral Wegovy rollout and beyond
Aug 7, 202620 min
The next frontier in patient support: Connected data, AI and personalized engagement (Sponsored)
Aug 6, 202626 min
Inside Noble’s connected approach to patient support (Sponsored)
Aug 3, 202615 min
Psychedelics, peptides and GLP-1s
Jul 31, 202625 min
GSK’s first lung cancer approval, a new IPO path and more
Jul 24, 202611 min